Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in Non-obstructive Coronary Artery Disease (VICTORION-PLAQUE)
NCT05360446Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Primary completion
- Oct 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in coronary artery disease (CAD) comparing Placebo + Statin with Inclisiran + Statin (2 arms). Primary endpoint: Percentage change in total coronary atheroma volume at 24 months. Started Jul 2022; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05360446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360446.